Above and Beyond Cancer Therapy: Translating Biomaterials into the Clinic

João Conde

doi:10.1016/j.trecan.2020.04.008

Above and Beyond Cancer Therapy: Translating Biomaterials into the Clinic

João Conde

Research output: Contribution to journal › Short survey › peer-review

12 Citations (Scopus)

Abstract

Given extensive reports of anticancer nanomedicines in preclinical studies, why is there such a paucity of clinical trials using these therapies? Nanotechnology can certainly deliver, but we need to tackle the limitations that are impeding the translation of nanomedicines into the clinic and start benefiting from their full potential.

Original language	English
Pages (from-to)	730-732
Journal	Trends in Cancer
Volume	6
Issue number	9
Early online date	16 May 2020
DOIs	https://doi.org/10.1016/j.trecan.2020.04.008
Publication status	Published - Sept 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

biomaterials
cancer therapy
clinical translation
nanomedicine

Access to Document

10.1016/j.trecan.2020.04.008

Cite this

@article{e83d1e385e284171aefa89148625c41e,

title = "Above and Beyond Cancer Therapy: Translating Biomaterials into the Clinic",

abstract = "Given extensive reports of anticancer nanomedicines in preclinical studies, why is there such a paucity of clinical trials using these therapies? Nanotechnology can certainly deliver, but we need to tackle the limitations that are impeding the translation of nanomedicines into the clinic and start benefiting from their full potential.",

keywords = "biomaterials, cancer therapy, clinical translation, nanomedicine",

author = "Jo{\~a}o Conde",

year = "2020",

month = sep,

doi = "10.1016/j.trecan.2020.04.008",

language = "English",

volume = "6",

pages = "730--732",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "9",

}

TY - JOUR

T1 - Above and Beyond Cancer Therapy

T2 - Translating Biomaterials into the Clinic

AU - Conde, João

PY - 2020/9

Y1 - 2020/9

N2 - Given extensive reports of anticancer nanomedicines in preclinical studies, why is there such a paucity of clinical trials using these therapies? Nanotechnology can certainly deliver, but we need to tackle the limitations that are impeding the translation of nanomedicines into the clinic and start benefiting from their full potential.

AB - Given extensive reports of anticancer nanomedicines in preclinical studies, why is there such a paucity of clinical trials using these therapies? Nanotechnology can certainly deliver, but we need to tackle the limitations that are impeding the translation of nanomedicines into the clinic and start benefiting from their full potential.

KW - biomaterials

KW - cancer therapy

KW - clinical translation

KW - nanomedicine

UR - https://www.scopus.com/pages/publications/85084564154

U2 - 10.1016/j.trecan.2020.04.008

DO - 10.1016/j.trecan.2020.04.008

M3 - Short survey

C2 - 32430152

AN - SCOPUS:85084564154

SN - 2405-8033

VL - 6

SP - 730

EP - 732

JO - Trends in Cancer

JF - Trends in Cancer

IS - 9

ER -

Above and Beyond Cancer Therapy: Translating Biomaterials into the Clinic

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this